| 臺大學術典藏 |
2020-12-02T02:34:36Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2020-12-02T02:34:25Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Pan-Chyr Yang; Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-11-25T08:43:50Z |
Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life
|
Hsieh C.-C.;Ho C.-C.;Lin Z.-Z.;Yu C.-J.;Jow G.-M.;Huang F.-Y.;Shih J.-Y.;Fei-Hsiu Hsiao; Hsieh C.-C.; Ho C.-C.; Lin Z.-Z.; Yu C.-J.; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; FEI-HSIU HSIAO |
| 臺大學術典藏 |
2020-11-19T03:19:42Z |
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
|
Lin Z.-Z.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; PO-HUANG LEE; Cheng A.-L.; Hsu H.-C. |
| 臺大學術典藏 |
2020-08-13T06:34:01Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang P.-C.; Pao W.; Cheng A.-L.; Yang C.-H.; Yu C.-J.; JIN-YUAN SHIH; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J. |
| 臺大學術典藏 |
2020-08-13T06:33:59Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
JIN-YUAN SHIH; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Yang P.-C.; Chen K.-Y.; Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:58Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Mok T.; Yang C.-H.; Leung L.; Lam K.C.; Lin C.-C.; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH; Lin Z.-Z.; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lin C.-C.;Hsu H.-H.;Sun C.-T.;Jin-Yuan Shih;Lin Z.-Z.;Yu C.-J.;Chen G.G.;Hsin M.K.Y.;Lam K.C.;Leung L.;Yang C.-H.;Mok T. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; JIN-YUAN SHIH; Lin Z.-Z.; Lan K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:27Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang J.C.-H.; Yu C.-J.; JIN-YUAN SHIH; Lin Z.-Z.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H. |
| 臺大學術典藏 |
2020-08-12T06:35:40Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.;Hsu C.;Chang Y.-C.;Chong-Jen Yu;Hsu C.-H.;Lin C.-C.;Cheng A.-L.;Yang P.-C.;Yang C.-H.; Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T06:34:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; CHONG-JEN YU; Chen K.-Y.; Shih J.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Chong-Jen Yu |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; CHONG-JEN YU; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Chong-Jen Yu |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU; Lin Y.-T.; Chen J.-S.; Liao W.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:42Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Lin C.-C.; Yang J.C.H.; Yu C.-J.; Lin Z.-Z.; Chen J.-S.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Hsu C.-L.; CHAO-CHI HO; Liao W.-Y.; Chen J.-S.; Lin Y.-T.; Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Chao-Chi Ho;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-08-12T02:42:37Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C. |
| 臺大學術典藏 |
2020-08-11T08:36:55Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Cheng A.-L.; Tien Y.-W.; PO-CHIN LIANG; Shao Y.-Y.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:54Z |
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.; Huang C.; PO-CHIN LIANG; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:51Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-07-21T06:46:22Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yang J.C.H.; Yu C.-J.; Lin C.-C.; Yao Z.-H.; Lin Z.-Z.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:16Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:16Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:09Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-07-21T06:09:04Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Shih J.-Y.; Yang J.C.-H.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; WEI-YU LIAO; Chen J.-S.; Lin Y.-T. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-05-26T09:27:22Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Kao W.-Y.;Lin Z.-Z;Yu C.-T;Kuo H.-P;Chang W.-C;Yu C.-J;Chung C.-Y;Ho M.-L;Wang J.-L;Huang M.-S;Chen C.-H;Chen H.-C;Hsia T.-C;Tsao C.-J;Su W.-C;Lai R.-S;Chu N.-M;Hsieh R.-K;Lin M.-C;Chang G.-C;Chen Y.-M;Chih-Hsin Yang;Perng R.-P; Perng R.-P; CHIH-HSIN YANG; Chen Y.-M; Chang G.-C; Lin M.-C; Hsieh R.-K; Chu N.-M; Lai R.-S; Su W.-C; Tsao C.-J; Hsia T.-C; Chen H.-C; Chen C.-H; Huang M.-S; Wang J.-L; Ho M.-L; Chung C.-Y; Yu C.-J; Chang W.-C; Kuo H.-P; Yu C.-T; Lin Z.-Z; Kao W.-Y. |
| 臺大學術典藏 |
2020-05-26T09:27:22Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang P.-C.;Pao W;Cheng A.-L;Bean J;Huang C.-L;Shun C.-T;Huang C.-J;Lin Z.-Z;Chen K.-Y;Tsai M.-C;Hu F.-C;Chang Y.-C;Shih J.-Y;Yu C.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Chang Y.-C; Hu F.-C; Tsai M.-C; Chen K.-Y; Lin Z.-Z; Huang C.-J; Shun C.-T; Huang C.-L; Bean J; Cheng A.-L; Pao W; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L; CHIH-HSIN YANG; Yeh K.-H; Hu F.-C; Chen K.-Y; Shih J.-Y; Lin Z.-Z; Yu C.-J; Cheng A.-L; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:18Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Lin C.-C;Hsu H.-H;Sun C.-T;Shih J.-Y;Lin Z.-Z;Yu C.-J;Chen G.G;Hsin M.K.Y;Lam K.C;Leung L;Chih-Hsin Yang;Mok T.; Lin C.-C; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; CHIH-HSIN YANG; Mok T. |
| 臺大學術典藏 |
2020-05-26T09:27:08Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Lai M.-S.;Chih-Hsin Yang;Kuo R.N.C;Shau W.-Y;Shao Y.-Y;Yang Y.-Y;Lin Z.-Z;Kuo Y.-H; Kuo Y.-H; Lin Z.-Z; Yang Y.-Y; Shao Y.-Y; Shau W.-Y; Kuo R.N.C; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:06Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Chengb A.-L.;Hsu C.-H;Hong R.-L;Chih-Hsin Yang;Chang D.-Y;Shao Y.-Y;Hu F.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Hu F.-C; Shao Y.-Y; Chang D.-Y; CHIH-HSIN YANG; Hong R.-L; Hsu C.-H; Chengb A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:05Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Laie M.-S.;Chih-Hsin Yang;Kuo R.N.-C;Yang Y.-Y;Shao Y.-Y;Shau W.-Y;Lin Z.-Z; Lin Z.-Z; Shau W.-Y; Shao Y.-Y; Yang Y.-Y; Kuo R.N.-C; CHIH-HSIN YANG; Laie M.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:04Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
Shao Y.-Y;Shau W.-Y;Lin Z.-Z;Chen H.-M;Kuo R;Chih-Hsin Yang;Lai M.-S.; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; Chen H.-M; Kuo R; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z;Shau W.-Y;Hsu C;Shao Y.-Y;Yeh Y.-C;Kuo R.N.-C;Hsu C.-H;Chih-Hsin Yang;Cheng A.-L;Lai M.-S.; Lin Z.-Z; Shau W.-Y; Hsu C; Shao Y.-Y; Yeh Y.-C; Kuo R.N.-C; Hsu C.-H; CHIH-HSIN YANG; Cheng A.-L; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:56Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Chen K.-H;Lai C.-L;Kuo R.N;Lin Z.-Z;Shau W.-Y;Chen H.-M;Shao Y.-Y;Liao B.-C; Liao B.-C; Shao Y.-Y; Chen H.-M; Shau W.-Y; Lin Z.-Z; Kuo R.N; Lai C.-L; Chen K.-H; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:52Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Cheng W.-F;Hsu C;Shao Y.-Y;Yang Y.-Y;Lai C.-L;Shau W.-Y;Kuo R;Lin Z.-Z;Kuo H.-Y; Kuo H.-Y; Lin Z.-Z; Kuo R; Shau W.-Y; Lai C.-L; Yang Y.-Y; Shao Y.-Y; Hsu C; Cheng W.-F; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Kuo S.-H.;Cheng A.-L;Lan K.-H;Lin Z.-Z;Shih J.-Y;Chen Y.-H;Hsu F.-M;Chih-Hsin Yang;Chiang Y; Chiang Y; CHIH-HSIN YANG; Hsu F.-M; Chen Y.-H; Shih J.-Y; Lin Z.-Z; Lan K.-H; Cheng A.-L; Kuo S.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.;Chih-Hsin Yang;Lin C.-C;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T;Chen J.-S;Liao W.-Y;Ho C.-C;Hsu C.-L;Yang C.-Y;Chen K.-Y;Lee J.-H;Lin Z.-Z;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Lin Y.-T; Chen J.-S; Liao W.-Y; Ho C.-C; Hsu C.-L; Yang C.-Y; Chen K.-Y; Lee J.-H; Lin Z.-Z; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non?�small-cell lung cancer patients
|
Yao Z.-H;Liao W.-Y;Ho C.-C;Chen K.-Y;Shih J.-Y;Chen J.-S;Lin Z.-Z;Lin C.-C;Chih-Hsin Yang;Yu C.-J.; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Yang C.-H.;Yang P.-C;Cheng A.-L;Chia-Chi Lin;Hsu C.-H;Yu C.-J;Chang Y.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Chang Y.-C; Yu C.-J; Hsu C.-H; Chia-Chi Lin; Cheng A.-L; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Chia-Chi Lin; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; Yang C.-H; Mok T. |
| 臺大學術典藏 |
2020-05-25T07:35:26Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
Yang S.-H; Chia-Chi Lin; Lin Z.-Z; Tseng Y.-L; Hong R.-L. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
Yu C.-J.;Yang J.C.-H;Chia-Chi Lin;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
|
Wang Y.-C; Wang D; Hung J.-H; Tang M; Lin Z.-Z; Chen T.-J; Cheng A.-L; Chen C.-S.; Yen-Shen Lu;Kashida Y;Kulp S.K;Wang Y.-C;Wang D;Hung J.-H;Tang M;Lin Z.-Z;Chen T.-J;Cheng A.-L;Chen C.-S.; YEN-SHEN LU; Kashida Y; Kulp S.K |
| 臺大學術典藏 |
2020-05-25T06:51:58Z |
The impact of diabetes mellitus on prognosis of early breast cancer in Asia
|
Lai M.-S.;Cheng A.-L;Kuo R.N.C;Chen H.-M;Yen-Shen Lu;Lin Z.-Z;Shau W.-Y;Shao Y.-Y;Chen W.-W; Chen W.-W; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; YEN-SHEN LU; Chen H.-M; Kuo R.N.C; Cheng A.-L; Lai M.-S. |
| 臺大學術典藏 |
2020-05-25T06:51:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T02:45:35Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y; Yang J.C.-H; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y; Lin Z.-Z; Lan K.-H; Cheng A.-L; Kuo S.-H. |
